Hyperhomocysteinemia as a risk factor for deep-vein thrombosis

New England Journal of Medicine

Volumn 334, Issue 12, 1996, Pages 759-762

  Den Heijer, Martin ^a   Köster, Ted ^b   Blom, Henk J ^c   Bos, Gerard M J ^a   Briët, Ernest ^b   Reitsma, Pieter H ^b   Vandenbroucke, Jan P ^b   Rosendaal, Frits R ^b  

^a LEYENBURG HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HOMOCYSTEINE; PROTEIN C; PROTEIN S;

ADOLESCENT; ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CASE-CONTROL STUDIES; FEMALE; HOMOCYSTEINE; HOMOCYSTINE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK FACTORS; SEX FACTORS; THROMBOPHLEBITIS;

EID: 0029921114     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199603213341203     Document Type: Article

References (25)

1. Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, ed Atherosclerotic cardiovascular disease, hemostasis, and endothelial function New York Marcel Dekker, 1993:183-236
2. Rees MM, Rodgers GM. Homocysteinemia. association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993;71 337-59.
3. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985;37 1-31.
4. Bienvenu T, Ankri A, Chadefaux B, Kamoun P Dosage de l'homocystéine plasmatique dans l'exploration des thromboses du sujet jaune. Presse Med 1991;20 985-8
5. Brattström L, Tengborn L, Lagerstedt C, Israelsson B, Hultberg B. Plasma homocysteine in venous thromboembolism. Haemostasis 1991;21:51-7.
6. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994;14:1080-3.
7. den Heijer M, Blom HJ, Gerrits WBJ, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995;345:882-5.
8. Koster T, Rosendaal FR, Briët E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study) Blood 1995;85.2756-61
9. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-6
10. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-5.
11. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM. Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation Lancet 1994,344:1453-7.
12. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369. 64-7
13. Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM. Homocysteine and other thiols in plasma and urine: automated determination and sample stability Clin Chem 1993;39.263-71.
14. te Poele-Pothoff MTWB, van den Berg M, Franken DG, et al Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 1995,32.218-20
15. Selhub J, Jacques PF, Bottom AG, et al Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995;332:286-91.
16. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians JAMA 1992;268:877-81
17. Rodgers GM, Kane WH, Pitas RE. Formation of factor Va by atherosclerotic rabbit aorta mediates factor Xa-catalyzed prothrombin activation J Clin Invest 1988;81.1911-9.
18. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75 895-901.
19. Blom HJ, van der Molen EF Pathobiochemical implications of hyperhomocysteinemia. Fibrinolysis 1994;8:Suppl 2 86-7.
20. Boers GHJ, Smals AGH, Trijbels FJM, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-15
21. Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HJ Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995;56:142-50.
22. Frosst P, Blom HJ, Goyette P, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-13.
23. den Heijer M, Bos GMJ, Gerrits WBJ, Blom HJ. Will a decrease of blood homocysteine by vitamin supplementation reduce the risk for vascular disease? Fibrinolysis 1994;8.Suppl 2.91-2.
24. Stampfer MJ, Willett WC. Homocysteine and marginal vitamin deficiency: the importance of adequate vitamin intake. JAMA 1993;270:2726-7
25. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 1995,332:328-9.